We are live on ! Find out more
NGNE icon

Neurogene
NGNE

36 hedge funds and large institutions have $53.7M invested in Neurogene in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

505% more capital inflows, than outflows

Capital inflows: $8.09M | Capital outflows: $1.34M

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

9% more funds holding

Funds holding: 33 → 36 (+3)

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

3.88% less ownership

Funds ownership: 70.83% → 66.95% (-3.9%)

Holders
36
Holders Change
+3
Holders Change %
+9.09%
% of All Funds
0.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
9
Reduced
9
Closed
7
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$3K

Top Buyers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
+$3.04M
2
Millennium Management
Millennium Management
New York
+$1.25M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$1.23M
4
BBA
Baker Bros. Advisors
New York
+$1.13M
5
Renaissance Technologies
Renaissance Technologies
New York
+$869K

Top Sellers

Rank Fund Capital Flow
1
Oxford Asset Management
Oxford Asset Management
United Kingdom
-$367K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$296K
3
Eversept Partners
Eversept Partners
New York
-$174K
4
JP Morgan Chase
JP Morgan Chase
New York
-$114K
5
Spark Investment Management
Spark Investment Management
New York
-$109K

NGNE Hedge Fund Activity: Q3 2019 in Review

36 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q3 2019, worth a combined $53.7M — up 36% from $39.3M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new NGNE positions and 7 closed out — a net gain of 3 holders — while 9 added to existing stakes and 9 trimmed.

The largest buyer was Opaleye Management, opening a new position worth an estimated $3.04M. The largest seller was Oxford Asset Management, cutting an estimated $367K.

  • 36 institutional investors held Neurogene (NGNE) as of Q3 2019, up from 33 in Q2 2019.
  • Funds reported $53.7M of Neurogene stock for Q3 2019, up 36% quarter-over-quarter.
  • 10 funds opened new Neurogene positions in Q3 2019 and 7 closed out, a net change of +3 holders.
  • The largest Neurogene buyer in Q3 2019 was Opaleye Management, an estimated $3.04M added.
  • The largest Neurogene seller in Q3 2019 was Oxford Asset Management, an estimated $367K sold.

Based on aggregated 13F filings for Q3 2019.